ABVC BioPharma EBIT

The latest EBIT for ABVC is $-5.1M as of June 2026. That compares with $-3.2M in the prior-year period — down 61.3% year over year. That is below the Industrials sector average of $190B. Investors often review this figure alongside ABVC BioPharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, ABVC's EBIT moved from $-3.2M to $-5.1M — a 61.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in ABVC BioPharma's operating scale or balance-sheet position.

Against Industrials companies, ABVC currently prints $-5.1M for EBIT, while the sector average sits near $190B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at ABVC BioPharma's growth, margins, and balance sheet.

A EBIT figure of $-5.1M for ABVC is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Industrials average is about $190B. Explore the charts below for those layers of context.

After noting ABVC's EBIT ($-5.1M), review year-over-year change from $-3.2M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.